Synthesis and Distribution of Drugs of Abuse and Related Compounds

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NIDA

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98027R00006OT

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

AN11

Additional Details
Set Aside

NONE

Place of Performance

-

SourceSAM
The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC), has issued a Sources Sought Notice (Procurement Identifier: 75N98027R00006OT) to identify qualified business organizations capable of supporting the synthesis and distribution of drugs of abuse and related compounds. This notice is intended solely for market research and information gathering purposes; it is not a solicitation for proposals, quotations, or abstracts, nor does it commit the Government to any future procurement action. Purpose and Scope: The primary objective of this potential procurement is to ensure the continued operation and enhancement of the NIDA Drug Supply Program, which is critical to advancing substance use research. The program provides the research community with a diverse inventory of authentic, pure, and controlled or uncontrolled drugs and chemical compounds, including both unlabeled and isotopically labeled substances (e.g., deuterium, tritium, carbon-14, iodine-125). These materials are essential for basic and applied research in drug abuse and related fields. Key Requirements and Expected Deliverables: Vendors must demonstrate the capability to synthesize, acquire, store, maintain, and distribute a wide range of drugs of abuse and related compounds. Specific requirements include: - Synthesis and acquisition of new and existing drugs, drug metabolites, and other chemical substances, including both unlabeled and labeled compounds (tritium, 125I, 14C, deuterium, 13C). - Maintenance of an inventory of hundreds of DEA-controlled and uncontrolled substances, including peptides (opioid and related neuropeptides), in quantities up to several kilograms, with appropriate secure and, where necessary, refrigerated storage. - Regular analysis, testing, and documentation to ensure all compounds maintain a purity of at least 95%, with re-purification as needed. - Replenishment of depleted inventory and incorporation of newly identified compounds relevant to drug abuse research. - Use and maintenance of the Drug Inventory Supply Control System (DISCS) database. - Processing of researcher requests and secure shipment of approved compounds. - Compliance with all DEA requirements for storage and handling, including the ability to receive and store substances in solution form. Mandatory Requirements: To be eligible, vendors must possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain registration for Schedule I controlled substances, as mandated by the Controlled Substances Act of 1970. Contracting Entity and Classification: This notice is issued by the National Institutes of Health (NIH), NIDA, under the Department of Health and Human Services. The applicable NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences, except Nanotechnology and Biotechnology), with Product Service Code AN11. There is no set-aside for small businesses or other socioeconomic categories at this time. Submission Instructions and Contact Information: Interested organizations are invited to submit capability statements that clearly document their expertise, experience, and capacity to fulfill the outlined requirements. Submissions should include details on staff qualifications, relevant project experience, corporate management capabilities, and examples of prior government contracts. Each response must also provide the organization’s UEI number, business classification, and contact information for technical and administrative points of contact. Responses must be submitted electronically in Microsoft Word or Adobe PDF format, limited to ten pages (excluding cover page, executive summary, resumes, and references), and conform to specified formatting guidelines. All submissions must be sent to Contract Specialist Shaun Rostad at [email protected] by 1:00 p.m. EST on November 20, 2026. Secondary contact is Joshua T. Lazarus ([email protected]). Special Considerations: This notice is for planning and information purposes only and does not constitute a request for proposals or a commitment to award a contract. The Government will not reimburse any costs incurred in responding to this notice. Respondents should not include proprietary, classified, or sensitive information in their submissions. The Government reserves the right to use non-proprietary information provided in any future solicitation. Contractors evaluating this opportunity should note that the requirements are highly specialized, involving controlled substances and demanding strict regulatory compliance, robust inventory management, and demonstrated experience in supporting research supply chains for drugs of abuse and related compounds. The opportunity is best suited for organizations with established capabilities in chemical synthesis, secure storage, regulatory compliance, and distribution within the research and development sector. For further details and updates, refer to the official notice at: https://sam.gov/opp/2ed32eb005e54aebabfa816c32d2a806/view.